Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
Abstract: At week 16, the genotypes in isolates from the abacavir/lamivudine/zidovudine group were M184V alone (n = 3 cases), WT (n = 3) and M184V plus thymidine analogue mutations (TAMs) (n = 1).
Abstract: At week 48, the most common genotype was M184V alone in the abacavir/ lamivudine/zidovudine group (median vRNA 1-2 log,10 below baseline), and M184V with or without TAMs in patients originally assigned to lamivudine/zidovudine.
Abstract: CONCLUSIONS: Abacavir retained efficacy against isolates with the M184V genotype alone.
Abstract: Despite detectable M184V in 74% of patients on lamivudine/zidovudine, addition of abacavir with or without another antiretroviral therapy resulted in a reduction in vRNA, with 42 of 65 (65%) patients having week 48 vRNA < 400 copies/
The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response.
Abstract: M184V is both common in the treated population and fitness-reducing.
Abstract: A number of studies, both of dual nucleoside therapy and HAART, have noted a residual treatment effect for 3TC despite the assumed or observed presence of M184V and high-level phenotypic resistance.
Abstract: The M184V mutation in the HIV-1 reverse transcriptase gene is primarily associated with rapid, high-level lamivudine (3TC) resistance.
Abstract: The full impact of M184V on therapeutic prospects will require further elucidation; ideally, the risk/benefit of preserving this substitution would be investigated in randomized trials.
Abstract: The speed and consistency with which this mutation is selected by 3TC under suboptimal viral suppression therefore makes M184V a
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.
Abstract: Drug-resistant mutants with a methionine-to-valine substitution at position 184 of reverse transcriptase (M184V) emerged within 5 weeks of initiation of therapy in four newborn macaques infected with simian immunodeficiency virus (SIVmac251) and treated with lamivudine (3TC) or emtricitabine [(-)-FTC] (two animals per drug).
Abstract: These data demonstrate that the M184V mutation in SIV conferred a slightly reduced fitness but did not affect disease outcome.
Abstract: Thus, this animal model mimics the rapid emergence of M184V mutants of HIV-1 during 3TC therapy of human patients.
Abstract: To further evaluate the effect of the M184V mutation on viral fitness and virulence, groups of juvenile macaques were inoculated with the molecular clone SIVmac239 wit
Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.
Abstract: Compared to placebo, significant reductions in HIV-1 RNA were observed for tenofovir DF-treated patients who had thymidine analog- (TAM), lamivudine- (M184V), NNRTI- or protease inhibitor-associated mutations.
Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1.
PMID: 12069983
2002
Antimicrobial agents and chemotherapy
Abstract: We cultured lamivudine-resistant human immunodeficiency virus type 1 (HIV-1) variants over an extended period of time in the presence of zidovudine and observed a premature reversion of the resistance-conferring M184V mutation.
Prevalence of genotypic resistance in untreated HIV patients in Spain.
PMID: 12072945
2002
European journal of clinical microbiology & infectious diseases
Abstract: Primary mutations in the reverse transcriptase gene were found in two (2.2%) samples: M41L, K70R and M184 V were found in one sample and K70R in another.
Genetic variation of the protease and reverse transcriptase genes in HIV-1 CRF04_cpx strains.
PMID: 12079565
2002
AIDS research and human retroviruses
Abstract: Substitutions classically associated with resistance to antiretroviral drugs were observed in six of seven samples, including G48V, V82A, L90M, M46I in the protease protein, and K70R, D69D/N, M184V, T215F, K103N in the reverse transcriptase protein.
Inclusion of full length human immunodeficiency virus type 1 (HIV-1) gag sequences in viral recombinants applied to drug susceptibility phenotyping.
PMID: 12088824
2002
Journal of virological methods
Abstract: Mutations known to cause retarded viral growth kinetics (RT M184V and PR I50V) were introduced and analyzed in parallel using both the new Five Prime HIV assay (FPH) and a standard recombinant virus assay (RVA).
Abstract: The M184V and I50V mutants produced up to 4.8- and 5.9-fold higher p24 antigen levels, respectively, with the FPH when compared to the cultures containing RVA-derived viruses.
Prevalence of HIV-1 polymerase gene mutations in pre-treated patients in Thailand.
PMID: 12118466
2002
The Southeast Asian journal of tropical medicine and public health
Abstract: The mutations associated with lamivudine resistance (M184V/I) were found most often (in 45.7% of individuals).
Prevalence of mutations related to HIV-1 antiretroviral resistance in Brazilian patients failing HAART.
HIV mutation literature information.
PMID: 
2002
Antiviral therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT